Drugdiscovery >> Drugs >> News
6394
Views
Pfizer’s perosnalized medicine drug for lung cancer not recommended by NICE - drugdiscovery.com
Pfizer’s perosnalized medicine drug for lung cancer not recommended by NICE - drugdiscovery.com


Xalkori (crizotinib) should be used as a later line treatment of ALK positive, advanced non small cell lung cancer (NSCLC) patients. NICE has acknowledged that the drug may offer better outcomes compared to standard chemotherapy to these patients, but has not recommended it for use within the NHS because it is not considered cost- effective.
Read More >>


Tags: Xalkori, crizotinib, advanced, non small cell lung cancer, NICE - August 16, 2013
Related Articles
16131
Views
Breakthrough therapy designation for Roche’s lung cancer drug alectinib Breakthrough therapy designation for Roche’s lung cancer drug alectinib
The FDA has granted breakthrough therapy designation for Roche’s promising investigational 2nd generation ALK inhibitor, used for the treatment of patients with metastatic non-small cell lung cance Read More >>

Tags: alectinib, lung cancer, breakthrough therapy designation, Roche, investigational drug, ALK inhibitor, metastatic non-small cell lung cancer, NSCLC, FDA

8655
Views
SOLIAIR™: New Respiratory Diseases Drug Discovery! SOLIAIR™: New Respiratory Diseases Drug Discovery!
SOLIAIR™ is a food supplement which has reported beneficial impact. Patients taking SOLIAIR™ reported a decrease in seasonal infections of the respiratory tract. The SOLIAIR™ is free of side eff Read More >>

Tags: Drug Development,Drug Discovery,Medicine Development,COPD Treatment,Asthma Solution,Bronchitis Therapy,Respiratory Diseases,Lung Infections,Breathing Disorders,healthcare investment,Drug Innovation,

7374
Views
Boehringer Ingelheim’s lung cancer drug afatinib (Giotrif ) approved in Europe Boehringer Ingelheim’s lung cancer drug afatinib (Giotrif ) approved in Europe
The European Commission has granted marketing authorization for afatinib, used as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC Read More >>

Tags: Giotrif, afatinib, locally advanced, metastatic, non-small cell lung cancer, NSCLC, EGFR mutation, EU, Europe

3220
Views
Perjeta’s benefits questioned Perjeta’s benefits questioned
Cinical data presented to NICE's independent appraisal committee left unclear how long Roche's Perjeta (pertuzumab) might extend patient’s lives, yet it costs much more than current NHS treatme Read More >>

Tags: Perjeta, Roche, NHS, NICE, advanced breast cancer

5935
Views
Gilotrif Approved for Late-Stage Lung Cancer Gilotrif Approved for Late-Stage Lung Cancer
The U.S. Food and Drug Administration approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth Read More >>

Tags: Gilotrif, metastatic non-small cell lung cancer

4961
Views
 Afatinib  is beneficial  for patients with distinct subtype of lung cancer Afatinib is beneficial for patients with distinct subtype of lung cancer
The results of LUX-Lung phase III trial show that Afatinib delays tumour growth and improves disease-related symptoms in patients with EGFR mutation positive, advanced non-small cell lung cancer (NSC Read More >>

Tags: Afatinib, lung cancer, EGFR mutation

3983
Views
Noxafil is recommended by the EU Committee Noxafil is recommended by the EU Committee
Merck announced that th Committee for Medicinal Products for Human Use of the European Medicines Agency has expressed a positive opinion and recommended Noxafil. The drug is in a new, investigational Read More >>

Tags: drug, Noxafil, Merck, tablet, EU.

6050
Views
Gilotrif Approved by FDA to Target Lung Cancer Gilotrif Approved by FDA to Target Lung Cancer
The U.S. Food and Drug Administration has approved a new drug that has been linked to treat lung cancer. Gilotrif (afatinib) has been approved for use and treatment for patients with a specific sub-ty Read More >>

Tags: Gilotrif, lung cancer, cancer, cure

1302
Views
Are Drugs Really Cheaper in the UK? Are Drugs Really Cheaper in the UK?
Generally, medicine prices are lower in the UK than anywhere in Europe. However, most of the inhabitatns think that rises going high. What could cause this feeling? Are the prices really rise? Read More >>

Tags: rise, medicine, medicine price, uk

3838
Views
NICE recommends MabThera for the treatment of a rare form of  vasculitis NICE recommends MabThera for the treatment of a rare form of vasculitis
UK’s NICE has given the recommendation for Roche's MabThera, to be used for the treatment of a rare autoimmune disorder called anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Read More >>

Tags: MabThera, ANCA associated vasculitis, Roche, UK

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013